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Edited by F. Peter GuengerichThe epidermal growth factor receptor (EGFR) is the most
intensively investigated receptor tyrosine kinase. Several EGFR
mutations and modifications have been shown to lead to
abnormal self-activation, which plays a critical role in carci-
nogenesis. Environmental air pollutants, which are associated
with cancer and respiratory diseases, can also activate EGFR.
Specifically, the environmental electrophile 1,2-
naphthoquinone (1,2-NQ), a component of diesel exhaust
particles and particulate matter more generally, has previously
been shown to impact EGFR signaling. However, the detailed
mechanism of 1,2-NQ function is unknown. Here, we demon-
strate that 1,2-NQ is a novel chemical activator of EGFR but
not other EGFR family proteins. We found that 1,2-NQ forms a
covalent bond, in a reaction referred to as N-arylation, with
Lys80, which is in the ligand-binding domain. This modifica-
tion activates the EGFR–Akt signaling pathway, which inhibits
serum deprivation–induced cell death in a human lung
adenocarcinoma cell line. Our study reveals a novel mode of
EGFR pathway activation and suggests a link between
abnormal EGFR activation and environmental pollutant–
associated diseases such as cancer.
The epidermal growth factor receptor (EGFR), called Erb-B2
receptor tyrosine kinase 1 (ErbB1)/human epidermal growth
factor receptor 1 (HER1), is the most well-established receptor
tyrosine kinase (RTK), and overactivation of the EGFR
signaling pathway is strongly linked to various types of cancer,
such as non–small-cell lung cancer, breast cancer, and glio-
blastoma (1). EGFR activation initiates signal transduction
through intracellular pathways, such as the extracellular
signal–regulated kinase/mitogen-activated protein kinase,
PI3K–protein kinase B (Akt), and Janus kinase/signal trans-
ducer and activator of transcription pathways, which result in
oncogenic processes, such as cell proliferation, migration, and
apoptosis resistance (2). In addition to genetic mutation of
EGFR (3), genetic mutation–independent EGFR activation also‡ These authors contributed equally to this work.
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BY license (http://creativecommons.org/licenses/by/4.0/).contributes to cancer (4). Another group demonstrated that
aberrant phosphorylation of EGFR by its ligands, such as
epithelial cell adhesion molecule, is associated with cancer
progression (5). Some studies have demonstrated that expo-
sure to air pollutants is correlated with the incidence of lung
and oral cancers (6). Furthermore, a recent study reported that
polycyclic aromatic hydrocarbons, which are the major class of
air pollutants, exhibit tumor-promoting effects (7). Although
environmental factors such as particulate matter (PM) with a
diameter of <2.5 μm (PM2.5) induce the phosphorylation of
EGFR (8), the relationship between environmental factors and
EGFR overactivation remains unclear.
Naphthalene containing gasoline is a major polycyclic aro-
matic hydrocarbon in the atmosphere (9), and its oxidation
products such as naphthoquinones (NQs) have become a focus
of interest because of their chemical properties based on
forming covalent bonds and acting as electron transfer agents
in redox reactions (10). Humans are exposed to NQs through
combustion of fossil (11) and diesel fuel (12) and from tobacco
smoke (13). NQs are reported to be formed from naphthalene
through incomplete combustion and photooxidation of
naphthalene in the atmosphere (14, 15) and the metabolic
activation of naphthalene mediated by a variety of xenobiotic
metabolizing enzymes in the body (Fig. S1) (10). In 2004, we
first identified 1,2-naphthoquinone (1,2-NQ) as its diacetyl
derivative from diesel exhaust particles and atmospheric
PM2.5 and established a method for quantifying 1,2-NQ by gas
chromatography–MS (16). Then, we also reported that levels
of 1,2-NQ in the particulate phase and gas phase at different
sites in Southern California were 5.8 to 246 pg/m3 and 109 to
445 pg/m3, respectively (10). Delgado-Saborit et al. (17) also
found that the total (particulate and gas phases) concentration
of 1,2-NQ was 3374 pg/m3 in a trafficked site in Birmingham,
United Kingdom. These suggest that 1,2-NQ is an abundant
ambient quinone derived from naphthalene, and atmospheric
concentrations of 1,2-NQ are dependent on site collected and
equipment used. Importantly, 1,2-NQ is particularly inter-
esting because of two toxicologically relevant reactions. First, it
acts as an electrophilic molecule and forms a covalent bond, a
reaction referred to as N- or S-arylation, with target proteins.J. Biol. Chem. (2021) 296 100524 1
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1,2-NQ, a novel chemical activator of EGFRFor example, endothelial nitric oxide synthase (18) and per-
oxiredoxin 6 (19) are known targets of 1,2-NQ; binding of 1,2-
NQ to these proteins results in disruption of the redox state
and the associated intracellular signaling pathway (20). In
addition, 1,2-NQ can act as an electron donor to produce
reactive oxygen species through redox cycling (10). Intrigu-
ingly, we previously demonstrated that 1,2-NQ phosphorylates
EGFR by inactivating protein-tyrosine phosphatase 1B
(PTP1B) (21), a negative regulator of EGFR (22). These lines ofFigure 1. Activation of Akt by 1,2-NQ via the PI3K–phosphoinositide-d
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insulin-like growth factor 1 receptor.
2 J. Biol. Chem. (2021) 296 100524evidence indicate that 1,2-NQ, which is a component of the air
pollutants, affects intracellular signal transduction, which may
lead to carcinogenesis. However, the detailed mechanisms by
which 1,2-NQ disrupts cellular homeostasis and promotes
oncogenic effects remain unclear.
In the present study, we show that 1,2-NQ directly forms a
covalent bond with Lys80, located in extracellular domain I of
EGFR, and activates EGFR–Akt signaling. In addition, 1,2-NQ
exerts a cytoprotective effect against serum deprivation–ependent protein kinase-1 pathway in A549 cells. A and B, cells were
icated concentrations of 1,2-NQ for 15 min. The lysates were analyzed by
lls were treated with the indicated concentrations of wortmannin (C), OSU-
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ressed as the mean ± SEM values. n = 3, *p < 0.05, **p < 0.01, and ***p <
none; Akt, protein kinase B; EGFR, epidermal growth factor receptor; IGF-1R,
1,2-NQ, a novel chemical activator of EGFRinduced apoptotic cell death. Our study suggests a novel
chemical modification of oncoproteins by air pollutants that
contribute to tumorigenesis through dysregulation of intra-
cellular signaling pathways.
Results
1,2-NQ activates Akt via the PI3K/phosphoinositide-dependent
protein kinase-1 pathway
To explore the effect of 1,2-NQ on oncogenic cellular
processes, we sought to determine whether 1,2-NQ affects the
level of phosphorylated Akt, an active form of Akt, in human
lung adenocarcinoma A549 cells. We analyzed the change in
Akt phosphorylation in A549 cells. Akt was activated by
1,2-NQ treatment in a concentration-dependent manner
(Fig. 1, A and B). Akt is phosphorylated by the PI3K/
phosphoinositide-binding protein (phosphoinositide-depen-
dent protein kinase-1 [PDK1]) pathway (23). To determine
whether 1,2-NQ activates Akt via the PI3K/PDK1 pathway, we
investigated the effect of specific inhibitors of PI3K and PDK1
on 1,2-NQ–induced Akt phosphorylation. Pretreatment with
wortmannin (a PI3K inhibitor), OSU-03012 (a PDK1 inhibi-
tor), or BX-795 (another PDK1 inhibitor) diminished the
1,2-NQ–mediated phosphorylation of Akt in a concentration-
dependent manner (Fig. 1, C–E and Fig. S2, A–C). These data
indicate that 1,2-NQ induces the phosphorylation of Akt via
the PI3K/PDK1 pathway.
PI3K–Akt signaling is initiated by growth factors, such as
EGF, insulin, and other extracellular stimuli (24). To deter-
mine the upstream target of 1,2-NQ in the PI3K/PDK1
pathway, we focused on the effect of 1,2-NQ on RTK family
members, such as EGFR, the insulin receptor (IR), and the
insulin-like growth factor 1 receptor (IGF-1R). To assess the
activation of EGFR, we evaluated the phosphorylation level of
EGFR after 1,2-NQ treatment. Exposure to 1,2-NQ enhanced
the phosphorylation of EGFR in a concentration-dependent
manner (Fig. 1F and Fig. S2D). As previously reported (21),
trans-1,2-dihydroxy-1,2-dihydronaphthalene, a non-
electrophilic analog of 1,2-NQ, failed to activate EGFR/Akt
signaling (Fig. 1G and Fig. S2, E and F). Therefore, the elec-
trophilicity of 1,2-NQ plays an indispensable role in its ability
to activate EGFR–Akt signaling. In addition, the phosphory-
lation of EGFR evoked by 1,2-NQ was observed in medium
with or without serum (Fig. S2G). On the other hand, the
phosphorylation of Akt was already detected in the media
containing serum, and the enhancement of phosphorylated
Akt formation by 1,2-NQ was only detected in the serum-free
medium but not in serum-containing medium (Fig. S2G).
Although serum contains some factors that can activate Akt, it
might be irrelevant to the reactivity of 1,2-NQ to EGFR.
We previously showed that 1,2-NQ modifies and inactivates
PTP1B, which acts as a negative regulator of RTKs, indicating
that inactivation of PTP1B by 1,2-NQ partly contributes to the
activation of EGFR (21). Surprisingly, although both IGF-1R
and IR are also regulated by PTP1B (22), exposure to 1,2-
NQ failed to induce the phosphorylation of these RTKs
(Fig. 1, H and I). Consistent with this evidence, the selectiveEGFR kinase inhibitor tyrphostin A25 suppressed 1,2-NQ-
induced phosphorylation of Akt in a concentration-dependent
manner (Fig. 1J and Fig. S2H). These data indicate that 1,2-NQ
may not only modify PTP1B but also directly activate EGFR.
To further explore the regulatory mechanism of 1,2-NQ, we
used the EGFR antagonist cetuximab, which can occupy the
ligand-binding site in EGFR (25, 26). We found that 1,2-NQ–
induced EGFR activation was dramatically diminished by
pretreatment with either cetuximab (Fig. 2A) or panitumumab,
which shares an epitope with cetuximab (Fig. 2B). Since EGFR
dimerization is required for its tyrosine kinase activity (27), we
investigated whether 1,2-NQ induces EGFR dimerization.
Intriguingly, 1,2-NQ induced EGFR dimerization, which was
decreased by pretreatment with cetuximab (Fig. 2, C and D).
From these lines of evidence, we hypothesized that 1,2-NQ
might directly bind and activate EGFR. To test this hypothe-
sis, we conducted an immunoprecipitation assay using specific
antibodies against EGFR and 1,2-NQ (28) and revealed that
1,2-NQ directly interacts with EGFR (Fig. 2E). On the other
hand, it has been previously reported that EGF stimulation in
cancer cells can promote both the homodimerization of EGFR
and heterodimerization of EGFR with human epidermal
growth factor receptor 2 (HER2)/Erb-B2 receptor tyrosine
kinase 2 (ErbB2) (29). Alternatively, some reports indicated
that EGF stimulates only homodimerization of EGFR, even
though the phosphorylation of HER2 was evident (30, 31). In
A549 cells, we detected the apparent and very weak formation
of homodimerization of EGFR and the heterodimerization of
EGFR/HER2 by treatment with EGF, respectively (Fig. S3). We
then investigated the ability of 1,2-NQ in stimulating hetero-
dimerization of EGFR with HER2/ErbB2. In A549 cells, we
detected the expression of EGFR (HER1/ErbB1), HER2/ErbB2,
and human epidermal growth factor receptor 3 (HER3)/ErbB3,
but not ErbB4, by Western blotting (Fig. 2F). Then, we
confirmed the effect of neureglin-1, a ligand for HERs but not
EGFR, on the phosphorylation of each receptor. As shown in
Figure 2F, treatment with neureglin-1 resulted in the signifi-
cant phosphorylation of HER2 and HER3. Interestingly, chal-
lenge with 1,2-NQ specifically stimulated the phosphorylation
of EGFR. In addition, 1,2-NQ could promote the homodime-
rization of EGFR but not heterodimerization of EGFR with
HER2/ErbB2 (Fig. S3). Thus, these results indicate that 1,2-NQ
can stimulate only the phosphorylation of EGFR and the for-
mation of homodimer (EGFR) in A549 cells.
1,2-NQ forms N-aryl bonds with EGFR to induce EGFR self-
activation
Protein nucleophiles, such as cysteine thiolates, histidine
imidazoles, and lysine amines, are reactive to form S- or N-aryl
bonds with electrophiles with α,β-unsaturated carbonyl
groups, including 1,2-NQ. 1,2-NQ covalently modifies cysteine
or histidine residues in its target proteins, for example, Kelch-
like ECH-associated protein 1 (32) and IκB kinase β (33). From
these lines of evidence, we speculated that 1,2-NQ forms either
S- or N-aryl bonds with EGFR. To identify the 1,2-NQ
modification sites in EGFR, we subjected the extracellularJ. Biol. Chem. (2021) 296 100524 3
Figure 2. 1,2-NQ directly induces EGFR dimerization and tyrosine phosphorylation. A and B, A549 cells were incubated with serum-free medium for
24 h and were then exposed to 10 μM 1,2-NQ or 10 ng/ml EGF for 10 min. Cells were pretreated with cetuximab (A) or panitumumab (B) for 3 h before
stimulation with 1,2-NQ or EGF. C, human embryonic kidney 293T cells were transiently transfected with pIDT-SMART (C-TSC) human EGFR-FLAG. Cells were
incubated with serum-free medium for 18 h and were then exposed to 10 μM 1,2-NQ for 10 min. Cells were pretreated with cetuximab for 3 h before
stimulation with 1,2-NQ. Immunoprecipitation was performed under nonreducing conditions for the detection of EGFR dimerization (upper) and under
reducing conditions for input analysis (lower). Western blotting was conducted with anti-1,2-NQ or anti-FLAG antibodies. D, quantification of 1,2-NQ–
induced EGFR dimerization in A549 cells. The relative level of EGFR dimers was normalized to the input EGFR level and shown as a fold change compared
with the control. Statistical analysis was carried out by one-way ANOVA with Bonferroni’s multiple comparisons test. All data are expressed as the mean ±
SEM values. n = 3, *p < 0.05, and **p < 0.01 versus control. E, A549 cells were cultured with serum-free medium for 24 h before exposure to 10 μM 1,2-NQ
for 10 min. Cell lysates were analyzed by immunoprecipitation using an anti-EGFR antibody and by Western blotting with anti-1,2-NQ or anti-EGFR anti-
bodies. F, A549 cells were incubated with serum-free medium for 24 h and were then exposed to 20 μM 1,2-NQ, 1 ng/ml EGF, or 1 ng/ml NRG-1 for 10 min.
1,2-NQ, 1,2-naphthoquinone; Akt, protein kinase B; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HER,
human epidermal growth factor receptor; NRG-1, neuregulin-1.
1,2-NQ, a novel chemical activator of EGFRdomain of 1,2-NQ–treated recombinant EGFR to trypsin
digestion and then subjected the obtained peptides to ultra–
high-performance liquid chromatography–tandem mass
spectrometry (UPLC–MSE) analysis. UPLC–MSE analysis
revealed that the 1,2-NQ modified the lysine (Lys, K) 80 and
Lys133 residues (Fig. 3A and Fig. S4). These lysine residues are
located in EGFR extracellular domain I, which interacts with4 J. Biol. Chem. (2021) 296 100524EGF (34). To determine whether these modification sites are
essential for 1,2-NQ–induced EGFR phosphorylation, we
substituted each lysine residue with an alanine (Ala, A). We
found that 1,2-NQ failed to induce the phosphorylation of the
EGFR K80A mutant but not the K133A mutant (Fig. 3, B and
C). These results suggest that the modification of K80 but not
K133 in EGFR is indispensable for EGFR–Akt pathway
Figure 3. 1,2-NQ forms N-arylation with EGFR at Lys80 and induces its phosphorylation. A, identification of 1,2-NQ–binding sites in recombinant
extracellular EGFR by ultra–high-performance liquid chromatography–tandem mass spectrometry analysis. Recombinant EGFR (5 μM) was incubated with
25 μM 1,2-NQ for 15 min at 25 C in 50 mM ammonium bicarbonate. Trypsin-digested peptides were analyzed by ultra–high-performance liquid
chromatography–tandem mass spectrometry. The mass data are shown in Fig. S4. B and C, human embryonic kidney 293T cells were transiently transfected
with WT, K80A, or K133A human EGFR. Cells were incubated with serum-free medium for 18 h after 6 h of transfection and were then stimulated with 10 μM
1,2-NQ for 10 min. The relative level of phosphorylated EGFR was normalized to the level of total EGFR. Statistical analysis was carried out by one-way
ANOVA with Bonferroni’s multiple comparisons test. All data are expressed as the mean ± SEM values. n = 3, *p < 0.05, and **p < 0.01 versus control.
1,2-NQ, 1,2-naphthoquinone; EGFR, epidermal growth factor receptor; ns, not significant.
1,2-NQ, a novel chemical activator of EGFRactivation by 1,2-NQ. Also, we compared the amino acid
sequence of the EGFR family members (Fig. S5). There are
many lysine residues present in the extracellular domains of all
EGFR family members. However, target lysine residues (K80
and 133) in EGFR do not exist in other types of EGFR mem-
bers. Therefore, we concluded that 1,2-NQ interacts with
EGFR (ErbB1) specifically through Lys80.
A previous study demonstrated that EGF phosphorylates
EGFR for up to 180 min, whereas 1,2-NQ induces persistent
activation of EGFR for up to 720 min (21). Based on a report
stating that N-arylated 1,2-NQ is more resistant to reducing
agents than S-arylated 1,2-NQ (35), we hypothesized that
1,2-NQ could form irreversible N-aryl bonds with EGFR and
induce prolonged EGFR activation. To test this hypothesis,
we evaluated the effect of GSH and DTT, another reducing
agent, on EGFR modification by 1,2-NQ. Neither of these
agents reversed the binding of 1,2-NQ to EGFR (Fig. S6).
From these data, we speculated that N-arylation of EGFR by
1,2-NQ might contribute to the persistent disruption in its
protein function.
EGFR signaling is strictly regulated by its internalization and
subsequent localization in endosomes, leading to its recycling
or degradation (36). Hence, we examined the effect of 1,2-NQ
on EGFR internalization. While EGFR localized at the plasma
membrane under basal conditions, treatment with its natural
ligand EGF induced the formation of EGFR puncta, indicating
EGFR internalization (Fig. 4A, lower panel). Interestingly, 1,2-
NQ also induced the formation of EGFR puncta, similar to
EGF treatment (Fig. 4A, upper panel). In addition, 1,2-NQ–
induced EGFR internalization was also suppressed by pre-
treatment with cetuximab (Fig. 4, B and C). Furthermore, we
confirmed by an immunofluorescence assay that 1,2-NQ
colocalizes with EGFR (Fig. 4D). These data support thehypothesis that 1,2-NQ interacts with EGFR and induces its
internalization via N-arylation.
1,2-NQ exerts antiapoptotic effects via EGFR–Akt signaling
Activation of the EGFR–PI3K–Akt signaling pathway in-
fluences apoptosis resistance, glucose metabolism, and auto-
phagy (2). Activated Akt can phosphorylate various substrates,
such as tuberous sclerosis complex 2 (TSC2), mechanistic
target of rapamycin (mTOR), and B-cell lymphoma 2–associ-
ated death promoter (BAD) (37, 38). It is known that these
targets exert protein synthesis, cell growth, and an anti-
apoptotic effect. Therefore, we sought to determine whether
1,2-NQ can phosphorylate mTOR, TSC2, and BAD in A549
cells. 1,2-NQ induced the phosphorylation of mTOR, TSC2,
and BAD in a concentration-dependent manner (Fig. 5, A–D).
Other groups have reported that serum deprivation causes
apoptotic death of A549 cells (39), which is inhibited by Akt
activity (40). To assess the effect of 1,2-NQ on apoptotic
stimuli, we incubated A549 cells with 1,2-NQ and induced
apoptosis by treatment with serum-free medium, which de-
prives cells of growth factors, in order to suppress EGFR-
dependent antiapoptotic effects (41). As a result, 1,2-NQ
suppressed serum deprivation–induced cell death (Fig. 6, A
and B). Apoptotic cells exhibiting nuclear condensation, a
typical signature of apoptosis, were assessed by Hoechst
staining and annexin V/propidium iodide (PI) staining, and we
also confirmed the cytoprotective effect of 1,2-NQ (Fig. 6, C–
E). In addition, we used specific inhibitors to examine whether
1,2-NQ exerts its antiapoptotic effect via the EGFR–Akt
signaling pathway. Treatment with these inhibitors signifi-
cantly abrogated the effect of 1,2-NQ (Fig. 6F). Finally, we
evaluated that the effect of 1,2-NQ on the cleavage of
poly(ADP-ribose) polymerase (PARP), by serum deprivation.J. Biol. Chem. (2021) 296 100524 5
Figure 4. 1,2-NQ induces EGFR internalization. A, cells were incubated with serum-free medium for 3 h and were then stimulated with 10 μM 1,2-NQ for
the indicated time. Immunofluorescence staining was performed to visualize EGFR internalization. The scale bar represents 50 μm. B, cells were pretreated
with cetuximab in serum-free medium for 3 h and were then exposed to 1,2-NQ for 10 min. Immunofluorescence staining was performed. The scale bar
represents 50 μm. C, quantification of EGFR internalization by exposure to 1,2-NQ or EGF for the indicated time. A549 cells were cultured in serum-free
medium for 3 h and were then exposed to 1,2-NQ or EGF. 1,2-NQ-treated cells were pretreated with cetuximab in serum-free medium for 3 h. Statisti-
cal analysis was carried out by two-way ANOVA with Bonferroni’s multiple comparisons test. The data are expressed as the mean ± SEM values. n = 3, *p <
0.05 versus control. D, cells were cultured in serum-free medium for 3 h and were then stimulated with 10 μM 1,2-NQ for the indicated time. Immuno-
fluorescence staining was conducted to visualize the colocalization of EGFR and 1,2-NQ. 1,2-NQ, 1,2-naphthoquinone; EGF, epidermal growth factor; EGFR,
epidermal growth factor receptor.
1,2-NQ, a novel chemical activator of EGFRAs shown Figure 6, G and H, 1,2-NQ significantly inhibited the
serum starvation–induced cleavage of PARP. These results
strongly suggested that 1,2-NQ attenuated serum deprivation–
induced apoptotic cell death through activation of EGFR–Akt
pathway. Our data indicate that 1,2-NQ induces activation of
the EGFR–Akt signaling pathway via binding directly to EGFR
and that this modification renders cancer cells resistant to
apoptotic stimuli.
Discussion
To date, many studies have demonstrated that ambient
pollutants can act as mutagens through the formation of DNA
adducts (42), leading to carcinogenesis. On the other hand, few
studies have indicated that chemical modification of proteins
by air pollutants may lead to carcinogenesis. Therefore, un-
derstanding the effects of environmental factors on the regu-
lation of oncogenic protein activity is important to prevent
carcinogenesis. In the present study, we showed that a
component of environmental air pollutants, 1,2-NQ, can
activate EGFR via N-arylation at Lys80. We also revealed that6 J. Biol. Chem. (2021) 296 1005241,2-NQ treatment and aberrant activation of EGFR–Akt
signaling promote apoptosis resistance in a cancer cell line,
which may correlate with carcinogenesis.
Carcinogenesis originates from both genetic and environ-
mental factors, indicating that these factors are related to
carcinogenesis (43). Regarding genetic factors, many studies
have demonstrated that gene mutations in EGFR are strongly
linked to lung cancer through the disruption of intracellular
signaling pathways (3). In addition, post-translational modifi-
cations of EGFR play an important role in regulating its acti-
vation, and dysregulation of these events may be associated
with carcinogenesis. For example, peroxide-dependent sulfe-
nylation of EGFR at Cys797 increases its kinase activity (44).
Although we previously reported that 1,2-NQ modifies PTP1B
at Cys121, leading to EGFR activation (21), here, we found that
1,2-NQ failed to activate the other RTKs, namely, IR and IGF-
1R (Fig. 1, H and I). These data indicate that 1,2-NQ primarily
induces phosphorylation in the EGFR–Akt signaling pathway
via N-arylation of EGFR and that the modification of PTP1B
by 1,2-NQ may synergistically contribute to the resulting
Figure 5. 1,2-NQ activates the downstream of Akt signaling pathway in A549 cells. A–D, cells were incubated with serum-free medium for 24 h before
exposure to 1,2-NQ for 30 min. The lysates were analyzed by Western blotting with anti-mTOR, anti-phosphorylated mTOR, anti-TSC2, anti-phosphorylated
TSC2, anti-BAD or anti-phosphorylated BAD antibody. Statistical analysis was carried out by one-way ANOVA with Bonferroni’s multiple comparisons test.
The data are expressed as the mean ± SEM values. n = 3, *p < 0.05, **p < 0.01, and ***p < 0.001 versus control. 1,2-NQ, 1,2-naphthoquinone; BAD, B-cell
lymphoma 2–associated death promoter; mTOR, mechanistic target of rapamycin; TSC2, tuberous sclerosis complex 2.
1,2-NQ, a novel chemical activator of EGFRsignal transduction. UPLC–MSE analysis revealed that 1,2-NQ
binds to EGFR at Lys80 and Lys133 (Fig. 3A). In addition, the
electrophilicity of 1,2-NQ is required for EGFR activation
(Fig. 1G), indicating that 1,2-NQ forms a covalent bond via a
Michael addition reaction. Protein nucleophiles such as
cysteine thiolates can react with 1,2-NQ, leading to S-arylation,
which is a reversible modification (45). On the other hand,
previous report has shown that EGF stimulation in cancer cells
promoted both the homodimerization of EGFR and hetero-
dimerization of EGFR with HER2/ErbB2 (29). We then
investigated whether 1,2-NQ stimulates the formation of
homodimers/heterodimers. Interestingly, treatment with 1,2-
NQ promoted the homodimerization of EGFR but not heter-
odimerization of EGFR with HER2/ErbB2. These results
strongly suggested that 1,2-NQ induces the receptor formation
of homodimers (EGFR) in A549 cells. Also, we compared the
amino acid sequence of the EGFR family members. There are
many lysine residues present in the extracellular domains of all
EGFR family members. However, as shown in Fig. S5, target
lysine residues (K80 and 133) in EGFR do not exist in other
types of EGFR members. Therefore, we concluded that 1,2-NQ
interacts with EGFR (ErbB1/HER1) specifically through Lys80.1,2-NQ is expected to form adducts not only on EGFR but
also other proteins. It is speculated that the adducts might
reflect targets that are independent of their half-lives and be
depend on the affinity of proteins to 1,2-NQ or the affinity of
1,2-NQ to proteins. On the other hand, lysine amines and
histidine imidazoles can undergo N-arylation, which is an
irreversible modification (35). Consistent with these findings,
the covalent bond between 1,2-NQ and EGFR was resistant to
reducing agents (Fig. S6). From these data, we speculated that
N-arylation by 1,2-NQ might contribute to the persistent
disruption in EGFR protein function. Consistent with this
hypothesis, a previous study demonstrated that compared with
EGF, 1,2-NQ prolongs EGFR activation (21). Since 1,2-NQ can
activate the extracellular signal–regulated kinase signaling
pathway via EGFR activation (46), we concluded that 1,2-NQ
affects other intracellular signaling pathways, resulting in
disruption of cellular homeostasis.
EGFR comprises four extracellular domains and an intra-
cellular region containing the tyrosine kinase domain. Its li-
gands, for example, EGF, bind with extracellular domains I and
III, leading to dimerization and autophosphorylation of EGFR
(27). UPLC–MSE and biochemical analyses revealed that 1,2-J. Biol. Chem. (2021) 296 100524 7
Figure 6. The antiapoptotic effect of 1,2-NQ is mediated via the epidermal growth factor receptor–PI3K–Akt pathway in A549 cells. A–D, cells were
stimulated with the indicated concentrations of 1,2-NQ for 10 min and were then incubated with serum-free medium. After 72 h, cells were observed using
a phase contrast microscope (A), and cell viability was then determined by a water soluble tetrazolium salt assay (B). The scale bar represents 100 μm. Cells
were treated with Hoechst 33342 for 30 min and were then observed using a fluorescence microscope. The arrows show the apoptotic cells. C and D, the
scale bar represents 50 μm. The data are expressed as the mean ± SEM values. *p < 0.05 and **p < 0.01 versus control. E, cells were incubated with serum-
free medium for 12 h and were then stimulated with 1,2-NQ at indicated concentrations for 10 min. After the incubation of serum-free medium for 24 h,
cells were stained by annexin V–FITC/propidium iodide and then observed using a fluorescence microscope. Annexin V/propidium iodide double positive
cells were counted as apoptotic cells. The data are expressed as the mean ± SEM values. *p < 0.05 versus 0 μM 1,2-NQ. F, cells were cultured with serum-free
medium for 24 h and were then exposed to 1,2-NQ (10 μM) for 10 min after treatment with LY294002 (10 μM) and OSU-03012 (5 μM) for 12 h. Cells were
treated with tyrphostin A25 (100 μM) in serum-free medium for 24 h after stimulation with 10 μM 1,2-NQ. After 72 h, cell viability was determined by a water
soluble tetrazolium salt assay. G and H, cells were stimulated with 1,2-NQ for 10 min and were then incubated with serum-free medium for 24 h. The lysates
were analyzed by Western blotting with anti-PARP or anticleaved PARP antibodies. Statistical analysis was carried out by two-way ANOVA with Bonferroni’s
multiple comparisons test. The data are expressed as the mean ± SEM values. *p < 0.05 and ***p < 0.001 between the two indicated groups. 1,2-NQ, 1,2-
naphthoquinone; PARP, poly(ADP-ribose) polymerase.
1,2-NQ, a novel chemical activator of EGFRNQ binds with EGFR at Lys80 (Fig. 3A), indicating that Lys80
in EGFR is indispensable for 1,2-NQ–induced EGFR activa-
tion. Interestingly, the endogenous ligand EGF binds with
EGFR via domains I and III, whereas 1,2-NQ binds only with
domain I and can induce the phosphorylation of EGFR. We
confirmed that no mutations or variants at Lys80, which is8 J. Biol. Chem. (2021) 296 100524associated with cancer, are reported in the Catalogue Of So-
matic Mutations In Cancer (https://cancer.sanger.ac.uk/
cosmic) (47). However, another study reported that muta-
tions in extracellular domains I (R108K) and II (A209V) of
EGFR in glioblastoma lead to ligand-independent phosphory-
lation (48). These mutations may lead to conformational
1,2-NQ, a novel chemical activator of EGFRchanges in the extracellular regions of EGFR, resulting in the
induction of ligand-independent EGFR phosphorylation (48,
49). Furthermore, the G33K and N56K mutations, which are
also located in domain I, cause ligand-independent EGFR
phosphorylation in head and neck cancer (50). These muta-
tions may also cause abnormal phosphorylation by altering
EGFR structural dynamics. These reports suggest that
conformational changes in the extracellular regions of EGFR
can affect its phosphorylation and signal transduction.
Although further structural studies are needed to understand
the exact mechanisms, we speculate that N-arylation of K80 by
1,2-NQ causes a conformational change in EGFR and then
induces ligand-independent EGFR phosphorylation.
We also elucidated whether 1,2-NQ exerted an anti-
apoptotic effect in A549 cells to protect against serum depri-
vation (Fig. 6). In the early stage of carcinogenesis, cancer cells
are exposed to nutrient deprivation because of insufficient
vascularization (51). Our results showed that the number of
annexin V/PI-positive cells, which indicates apoptosis, signif-
icantly decreased after treatment with 1,2-NQ. This result
together with the data on cell viability, morphological changes,
and Hoechst staining suggested that 1,2-NQ has the ability to
inhibit cell death induced by serum starvation via EGFR–Akt
signaling. Therefore, our data suggest that 1,2-NQ can pro-
mote the survival of cancer cells under nutrient-poor condi-
tions by activating Akt signaling. These lines of evidence
suggest that cigarette smoking may exacerbate respiratory
diseases and carcinogenesis via N-arylation of EGFR.
It has been widely recognized that not only genetic mutation
but also aberrant functional modification of EGFR contributes
to the pathogenesis of cancer. However, the effect of envi-
ronmental factors such as ambient air pollutants on EGFR
activity remains poorly understood so far. In this study, we
demonstrated that the air pollutant 1,2-NQ activates the
EGFR–Akt signaling pathway (Fig. 1). In addition to our study,
another recent study showed that exposure to PM2.5 con-
taining 1,2-NQ increased the phosphorylation of EGFR and
Akt in mice (52). Taken together, these findings indicate that
the environmental air pollutant 1,2-NQ can induce EGFR–Akt
signaling via N-arylation of EGFR, leading to the inhibition of
serum starvation–induced apoptotic cell death. These data
emphasize that N-arylation by 1,2-NQ is a novel aberrant
chemical modification of EGFR and may contribute to carci-
nogenesis by inducing aberrant activation of EGFR–Akt
signaling. To our knowledge, this evidence is the first to
indicate that extracellular post-translational modifications
regulate EGFR activity. Our study sheds light on the mecha-
nism of EGFR overactivation by 1,2-NQ in environmental
factor–associated diseases such as cancer.
Experimental procedures
Reagents and antibodies
Antibodies against Akt, phospho-Akt (S473) (D9E), EGFR
(D38B1), phospho-EGFR (Y1068) (D7A5), HER2 (D8F12),
phosphor-HER2 (Y1221/1222) (6B12), HER3 (D22C5),
phosphor-HER3 (Y1289) (21D3), IR (4B8), phospho-IR(Y1146), IGF-IR (D23H3), p-IGF-IR (Y1131) (DA7A8),
mTOR (7C10), phosphor-mTOR (S2448) (D9C2), TSC2
(D93F12), phosphor-TSC2 (T1462) (5B12), BAD (D24A9) and
phospho-BAD (S136) (D25H8), PARP, and cleaved PARP
(Asp214) (D64E10) were purchased from Cell Signaling
Technology. Antibodies against FLAG (DYKDDDDK) were
purchased from Sigma–Aldrich. Antibodies against 1,2-NQ
were generated as previously described (21). OSU-03012 and
LY294002 were purchased from ChemScene. Tyrphostin A25
was purchased from Wako. Recombinant human neuregulin-1
was purchased from Cell Signaling Technology. The expres-
sion vector for FLAG-tagged WT EGFR (pIDT-SMART [C-
TSC] EGFR-FLAG) was prepared as previously described (53).
Western blotting
Cells were washed with PBS and lysed in ice-cold radio-
immunoprecipitation assay buffer (40 mM Tris–HCl [pH 8.0],
150 mM NaCl, 0.5% [w/v] sodium deoxycholate, 0.1% [w/v]
SDS, 1% [v/v] Nonidet P-40, and a protease inhibitor cocktail)
on ice for 5 min. After quantification via the bicinchoninic
acid assay method, protein samples were boiled in 1× Laemmli
SDS sample buffer (62.5 mM Tris–HCl [pH 6.8], 5% v/v 2-
mercaptoethanol, 2% [w/v] SDS, and 10% [v/v] glycerol) for
5 min. Samples were subjected to Western blotting as previ-
ously described (54). For immunoprecipitation studies, cell
lysates were incubated first with an anti-FLAG (M2) mAb
(1:250) for 2 h at 4 C and then with protein G Sepharose
beads for 2 h at 4 C. After wash with radio-
immunoprecipitation assay buffer, samples were eluted from
the beads with nonreducing or reducing 1× Laemmli SDS
sample buffer.
Cell culture and transfection
A549 human lung adenocarcinoma epithelial cells and hu-
man embryonic kidney 293T cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) heat-
inactivated fetal bovine serum at 37 C in a humidified at-
mosphere of CO2/95% air. Transfections were conducted us-
ing polyethylenimine MAX (Polysciences, Inc) according to
the manufacturer’s instructions.
UPLC–MSE
Recombinant human EGFR (hEGFR; Sino Biological, Inc;
5 μM) was incubated with dimethyl sulfoxide as a control or
25 μM 1,2-NQ for 15 min at 25 C in 50 mM ammonium bi-
carbonate. A solution of Tris(2-carboxyethyl)phosphine
(2.5 mM) in ammonium bicarbonate was added to the mixture
and incubated for 20 min at 25 C. Proteins in the mixture were
alkylated by treatment with 5 mM 2-iodoacetamide at 25 C in
the dark for 20 min. hEGFR (3.45 μg) was digested with Glu-C
(100 ng) for 16 h at 37 C, and an aliquot of 1% (v/v) formic acid
was then added to the resulting peptides. Analyses were per-
formed using a nanoAcquity UPLC system (Waters Co)
equipped with a BEH130 nanoAcquity C18 column
(100 mm × 75 μm i.d., 1.7 μm) held at 35 C according to
procedures described previously, with slight modification (55).J. Biol. Chem. (2021) 296 100524 9
1,2-NQ, a novel chemical activator of EGFRIn brief, mobile phases A (water containing 0.1% [v/v] formic
acid) and B (acetonitrile containing 0.1% [v/v] formic acid) were
linearly mixed by using a gradient program. The flow rate was
0.3 μl/min, and the mobile phase composition was as follows:
3% B for 1 min, a linear increase over 74 min to 40% B, 40% B
for 4 min, a linearly increase over 1 min to 95% B, and 95% B for
5 min. The eluted peptides were then transferred to the
nanoelectrospray source of a quadrupole time-of-flight mass
spectrometer (SYNAPT High Definition Mass Spectrometry
System, Waters Co). The system was controlled, and mass
spectra were analyzed with Waters MassLynx software, version
4.1 (Waters Co). An electrospray ionization source was used,
with a capillary voltage of 2.5 kV and a sampling cone voltage of
35 V. A low (6 eV) or increasing (step from 30 to 45 eV)
collision energy was used to generate either intact peptide
precursor ions (low energy) or peptide productions (increasing
energy). The source temperature was 100 C, and the detector
was operated in positive-ion mode. Data were collected in
centroid mode from m/z 300 to 2000. All analyses were per-
formed with an independent reference, Glu-1-fibrinopeptide B
(m/z 785.8426). BiopharmaLynx, version 1.2 software (Waters)
was used for baseline subtraction and smoothing, deisotoping,
de novo peptide sequence identification, and database search
against the sequence of hEGFR (NP_005219.2). The following
default search settings were applied: enzyme, Glu-C; maximum
missed cleavage, 3; variable modifications, carbamidomethyl
(C); and 1,2-NQ (C, H, K); mass tolerance, ± 30 ppm; MS ion
intensity threshold, 250 counts; MSE ion intensity threshold,
100 counts. All peptides were filtered by applying a minimum
intensity threshold of 5% to exclude peptides at low intensity.
The matched masses of hEGFR with or without 1,2-NQ
covered 100% of the hEGFR sequence. Peptide fragments
containing 1,2-NQ were identified on the basis of their calcu-
lated m/z values (fragment +156.02). Their equivalent mass was
added to the mass of the unmodified peptide as 1,2-NQ cova-
lently binds protein thiol through the 1,4-Michael addition
reaction to form 1,2-NQH2, which easily undergoes auto-
oxidation to form protein-1,2-NQ.
PCR-based site-directed mutagenesis
PCR-based site-directed mutagenesis was performed with
PrimeSTAR Max DNA polymerase (Takara Bio Inc) using the
following primer pairs: K80A EGFR forward, 5’-TTC TTA
GCG ACC ATC CAG GAG GTG GC-3’ and K80A EGFR
reverse, 5’-GAT GGT CGC TAA GAA GGA AAG ATC AT-
3’; K133A EGFR forward, 5’-CCG GAC TGA GCG AGC TGC
CCA TGA GAA ATT TA-3’ and K133A EGFR reverse, 5’-
TGG GCA GCT CCG CCA GTC CGG TTT TAT TTG-3’.
The PCR products were incubated with DpnI for 1 h at 37 C.
The mutated plasmid DNA was transformed into competent
Escherichia coli DH5α cells. The mutated sequences were
confirmed by Sanger sequencing.
Immunocytochemistry
A549 cells were cultured on coverslips. After exposure to
1,2-NQ, cells were washed 3 times with PBS, fixed with 4% (v/10 J. Biol. Chem. (2021) 296 100524v) paraformaldehyde in PBS for 20 min at RT, washed 3 times
with PBS, and permeabilized with PBS-Triton-X (0.1% [v/v])
for 10 min at 4 C. Cells were then blocked with 1% (w/v)
bovine serum albumin in PBS for 1 h at RT and incubated with
primary anti-EGFR and/or anti-1,2-NQ antibodies for 2 h at
RT. Cells were washed 3 times with PBS and were then
incubated with Alexa 488- or 594-conjugated goat anti-rabbit
or mouse IgG antibodies (Invitrogen; 2 mg/ml, 1:400) for
30 min at RT. Coverslips were mounted with Vectashield with
40,6-diamidino-2-phenylindole (Vector Laboratories, Inc) for
15 min at RT, fluorescence was examined using a fluorescence
microscope (FSX100; Olympus). Cells containing puncta were
counted as EGFR-internalized cells.
Assessment of cell viability
Cell viability was measured in triplicate wells of 12-well plates
by a Cell Counting Kit-8 (Dojindo). A549 cells were serum
starved for 24 h before exposure to 1,2-NQ. Cells were treated
with LY294002, OSU-03012, or tyrphostin A25 for 12 h or 24 h
before stimulation with 1,2-NQ. After 72 h, water soluble
tetrazolium salt reagents were added to cells in a 12-well plate,
and the cells were incubated at 37 C for 1 h. Cell viability was
assessed by measuring the OD450. The number of apoptotic
nuclei in A549 cells was determined by Hoechst 33342 staining
and evaluation with a fluorescence microscope (FSX100;
Olympus). Condensed nuclei were considered apoptotic nuclei.
Annexin V/PI staining
Annexin V/PI staining was performed by the provided
protocol of annexin V-FITC Apoptosis Detection Kit (Nacalai
Tesque). Briefly, cells were incubated with serum-free medium
for 24 h. 1,2-NQ was treated at the 12 h of serum-free incu-
bation for 10 min and then washed out. Cells were incubated
with the solution containing annexin V–FITC/PI at room
temperature for 15 min. The samples were immediately
observed by fluorescence microscope (BZ-X810; Keyence).
Statistical analysis
All experiments were independently performed at least 3
times. All data are expressed as the mean ± SEM values. Sta-
tistical comparisons were conducted using ANOVA with post
hoc Bonferroni correction or Student’s t test in GraphPad
Prism 7 (GraphPad Software). p Values of <0.05 were
considered to indicate significant differences.
Data availability
All data are contained within the article and the supporting
information.
Supporting information—This article contains supporting
information.
Acknowledgments—We thank M. Sakaguchi (Okayama University)
for providing plasmids and advice; we also thank Y. Okamoto, H.
Nakai, and M. Matsumoto for technical assistance.
1,2-NQ, a novel chemical activator of EGFRAuthor contributions—K. N., K. H., and T. T. performed most of the
experiments and wrote the initial article. N. T., K. S., and S. T.
provided biochemical data and helped write the article. Y. A. and Y.
K. performed LC–MS analysis and helped write the article. T. U.
conceived and designed the study, analyzed the data, and wrote the
article.
Funding and additional information—This work was supported in
part by Grants-in-Aid for Scientific Research (B) (18H02579),
Challenging Exploratory Research (19K22498) (to T. U.), and Sci-
entific Research (S) (18H05293) (to Y. K.) from the Ministry of
Education, Culture, Sports and Technology (MEXT) of Japan and
by the Smoking Research Foundation (to T. U.).
Conflict of interest—The authors declare that they have no conflicts
of interest with the contents of this article.
Abbreviations—The abbreviations used are: 1,2-NQ, 1,2-
naphthoquinone; Akt, protein kinase B; BAD, B-cell lymphoma
2–associated death promoter; ErbB1, Erb-B1 receptor tyrosine ki-
nase 1; ErbB2, Erb-B2 receptor tyrosine kinase 2; EGFR, epidermal
growth factor receptor; hEGFR, human EGFR; HER, human
epidermal growth factor receptor; IGF-1R, insulin-like growth fac-
tor 1 receptor; IR, insulin receptor; PARP, poly(ADP-ribose) poly-
merase; PDK1, phosphoinositide-dependent protein kinase-1; PM,
particulate matter; PTP1B, protein-tyrosine phosphatase 1B; RTK,
receptor tyrosine kinase; TSC2, tuberous sclerosis complex 2;
UPLC–MSE, ultra–high-performance liquid chromatography–
tandem mass spectrometry.
References
1. Sigismund, S., Avanzato, D., and Lanzetti, L. (2018) Emerging functions of
the EGFR in cancer. Mol. Oncol. 12, 3–20
2. Wee, P., and Wang, Z. (2017) Epidermal growth factor receptor cell
proliferation signaling pathways. Cancers 9, 1–45
3. da Cunha Santos, G., Shepherd, F. A., and Tsao, M. S. (2011) EGFR
mutations and lung cancer. Annu. Rev. Pathol. Mech. Dis. 6, 49–69
4. Sasaki, T., Hiroki, K., and Yamashita, Y. (2013) The role of epidermal
growth factor receptor in cancer metastasis and microenvironment.
Biomed. Res. Int. 2013, 1–9
5. Pan, M., Schinke, H., Luxenburger, E., Kranz, G., Shakhtour, J., Libl, D.,
Huang, Y., Gaber, A., Pavsic, M., Lenarcic, B., Kitz, J., Jakob, M.,
Schwenk-Zieger, S., Canis, M., Hess, J., et al. (2018) EpCAM ectodomain
EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-
mesenchymal transition through modulation of phospho-ERK1/2 in head
and neck cancers. PLoS Biol. 16, e2006624
6. Hecht, S. S. (2002) Cigarette smoking and lung cancer: Chemical
mechanisms and approaches to prevention. Lancet Oncol. 3, 461–469
7. Misaki, K., Takamura-Enya, T., Ogawa, H., Takamori, K., and Yanagida,
M. (2016) Tumour-promoting activity of polycyclic aromatic hydrocar-
bons and their oxygenated or nitrated derivatives. Mutagenesis 31, 205–
213
8. Huang, L., Pu, J., He, F., Liao, B., Hao, B., Hong, W., Ye, X., Chen, J.,
Zhao, J., Liu, S., Xu, J., Li, B., and Ran, P. (2017) Positive feedback of the
amphiregulin-EGFR-ERK pathway mediates PM2.5 from wood smoke-
induced MUC5AC expression in epithelial cells. Sci. Rep. 7, 1–12
9. Fraser, M. P., Cass, G. R., Simoneit, B. R. T., and Rasmussen, R. A. (1998)
Air quality model evaluation data for organics. 5. C6-C22 nonpolar and
semipolar aromatic compounds. Environ. Sci. Technol. 32, 1760–1770
10. Kumagai, Y., Shinkai, Y., Miura, T., and Cho, A. K. (2012) The chemical
biology of naphthoquinones and its environmental implications. Annu.
Rev. Pharmacol. Toxicol. 52, 221–247
11. Eiguren-Fernandez, A., Miguel, A. H., DiStefano, E. W., Schmitz, D. A.,
Cho, A. K., Thurairatnam, S., Avol, E. L., and Froines, J. R. (2008)Atmospheric distribution of gas- and particle-phases quinones in
Southern California. Aerosol Sci. Technol. 42, 854–861
12. Chung, M. Y., Lazaro, R. A., Lim, D., Jackson, J., Lyon, J., Rendulic, D., and
Hasson, A. S. (2006) Aerosol-borne quinones and reactive oxygen species
generation by particulate matter extracts. Environ. Sci. Technol. 40, 4880–
4886
13. Jakober, C. A., Riddle, S. G., Robert, M. A., Destaillats, H., Charles, M. J.,
Green, P. G., and Kleeman, M. J. (2007) Quinone emissions from gasoline
and diesel motor vehicles. Environ. Sci. Technol. 41, 4548–4554
14. Walgraeve, C., Demeestere, K., Dewulf, J., Zimmermann, R., and Van
Langenhove, H. (2010) Oxygenated polycyclic aromatic hydrocarbons in
atmospheric particulate matter: Molecular characterization and occur-
rence. Atmos. Environ. 44, 1831–1846
15. Kautzman, K. E., Surratt, J. D., Chan, M. N., Chan, A. W. H., Hersey, S. P.,
Chhabra, P. S., Dalleska, N. F., Wennberg, P. O., Flagan, R. C., and
Seinfeld, J. H. (2010) Chemical composition of gas- and aerosol-phase
products from the photooxidation of naphthalene. J. Phys. Chem. A
114, 913–934
16. Cho, A. K., Schmitz, D. A., Ying, Y., Rodriguez, C. E., DiStefano, E. W.,
Kumagai, Y., Miguel, A., Eiguren, A., Kobayashi, T., Avol, E., and
Froines, J. R. (2004) Determination of four quinones in diesel exhaust
particles, SRM1649a and, atmospheric PM2.5. Aerosol Sci. Technol. 38,
68–81
17. Delgado-Saborit, J. M., Alam, M. S., Godri-Pollitt, K. J., Stark, C., and
Harrison, R. M. (2013) Analysis of atmospheric concentrations of qui-
nones and polycyclic aromatic hydrocarbons in vapour and particulate
phases. Atmos. Environ. 77, 974–982
18. Sun, Y., Taguchi, K., Sumi, D., Yamano, S., and Kumagai, Y. (2006) In-
hibition of endothelial nitric oxide synthase activity and suppression a
component of diesel exhaust particles. Arch. Toxicol. 80, 280–285
19. Takayama, N., Iwamoto, N., Sumi, D., Shinkai, Y., Tanaka-Kagawa, T.,
Jinno, H., and Kumagai, Y. (2011) Peroxiredoxin 6 is a molecular target
for 1,2-naphthoquinone, an atmospheric electrophile, in human pulmo-
nary epithelial A549 cells. J. Toxicol. Sci. 36, 817–821
20. Kumagai, Y., Abiko, Y., and Cong, N. L. (2016) Chemical toxicology of
reactive species in the atmosphere: Two decades of progress in an elec-
tron acceptor and an electrophile. J. Toxicol. Sci. 41, SP37–SP47
21. Iwamoto, N., Sumi, D., Ishii, T., Uchida, K., Cho, A. K., Froines, J. R., and
Kumagai, Y. (2007) Chemical knockdown of protein-tyrosine phosphatase
1B by 1,2-naphthoquinone through covalent modification causes persis-
tent transactivation of epidermal growth factor receptor. J. Biol. Chem.
282, 33396–33404
22. Kenner, K. A., Anyanwu, E., Olefsky, J. M., and Kusari, J. (1996) Protein-
tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like
growth factor-I-stimulated signaling. J. Biol. Chem. 271, 19810–19816
23. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J.,
Reese, C. B., and Cohen, P. (1997) Characterization of a 3-
phosphoinositide-dependent protein kinase which phosphorylates and
activates protein kinase Bα. Curr. Biol. 7, 261–269
24. Hers, I., Vincent, E. E., and Tavaré, J. M. (2011) Akt signaling in health
and disease. Cell. Signal. 23, 1515–1527
25. Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., and
Ferguson, K. M. (2005) Structural basis for inhibition of the epidermal
growth factor receptor by cetuximab. Cancer Cell 7, 301–311
26. Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., and
Tasker, A. S. (2016) The panitumumab EGFR complex reveals a binding
mechanism that overcomes cetuximab induced resistance. PLoS One 11,
1–11
27. Kovacs, E., Zorn, J. A., Huang, Y., Barros, T., and Kuriyan, J. (2015)
A structural perspective on the regulation of the epidermal growth factor
receptor. Annu. Rev. Biochem. 84, 739–764
28. Endo, A., Sumi, D., and Kumagai, Y. (2007) 1,2-Naphthoquinone disrupts
the function of cAMP response element-binding protein through cova-
lent modification. Biochem. Biophys. Res. Commun. 361, 243–248
29. Goldman, R., Levy, R. B., Peles, E., and Yarden, Y. (1990) Hetero-
dimerization of the ErbB-1 and ErbB-2 receptors in human breast car-
cinoma cells: A mechanism for receptor transregulation. Biochemistry 29,
11024–11028J. Biol. Chem. (2021) 296 100524 11
1,2-NQ, a novel chemical activator of EGFR30. Sakai, K., Yokote, H., Murakami-Murofushi, K., Tamura, T., Saijo, N., and
Nishio, K. (2007) Pertuzumab, a novel HER dimerization inhibitor, in-
hibits the growth of human lung cancer cells mediated by the HER3
signaling pathway. Cancer Sci. 98, 1498–1503
31. Laux, I., Jain, A., Singh, S., and Agus, D. B. (2006) Epidermal growth
factor receptor dimerization status determines skin toxicity to HER-
kinase targeted therapies. Br. J. Cancer 94, 85–92
32. Shinkai, Y., Abiko, Y., Ida, T., Miura, T., Kakehashi, H., Ishii, I., Nishida,
M., Sawa, T., Akaike, T., and Kumagai, Y. (2015) Reactive sulfur species-
mediated activation of the Keap1-Nrf2 pathway by 1,2-naphthoquinone
through sulfenic acids formation under oxidative stress. Chem. Res.
Toxicol. 28, 838–847
33. Sumi, D., Akimori, M., Inoue, K.-I., Takano, H., and Kumagai, Y. (2010) 1,2-
Naphthoquinone suppresses lipopolysaccharide dependent activation of
IKKβ/NF-κB/NOsignaling:An alternativemechanism for the disturbance of
inducible NO synthase-catalyzed NO formation. J. Toxicol. Sci. 35, 891–898
34. Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H.,
Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., and Yokoyama, S. (2002)
Crystal structure of the complex of human epidermal growth factor and
receptor extracellular domains. Cell 110, 775–787
35. Toyama, T., Shinkai, Y., Yazawa, A., Kakehashi, H., Kaji, T., and Kuma-
gai, Y. (2014) Glutathione-mediated reversibility of covalent modification
of ubiquitin carboxyl-terminal hydrolase L1 by 1,2-naphthoquinone
through Cys152, but not Lys4. Chem. Biol. Interact. 214, 41–48
36. Madshus, I. H., and Stang, E. (2009) Internalization and intracellular
sorting of the EGF receptor: A model for understanding the mechanisms
of receptor trafficking. J. Cell Sci. 122, 3433–3439
37. Danial, N. N. (2009) BAD: Undertaker by night, candyman by day.
Oncogene 27, 53–70
38. Dienstmann, R., Rodon, J., Serra, S. V., and Tabernero, J. (2014) Picking
the point inhibition: A comparative review of PI3K/AKT/mTOR pathway
inhibitors. Mol. Cancer Ther. 13, 1021–2031
39. Huang, Y., Chan, A. M. L., Liu, Y., Wang, X., and Holbrook, N. J. (1997)
Serum withdrawal and etoposide induce apoptosis in human lung car-
cinoma cell line A549 via distinct pathways. Apoptosis 2, 199–206
40. Kuzman, J. A., Gerdes, A. M., Kobayashi, S., and Liang, Q. (2005) Thyroid
hormone activates Akt and prevents serum starvation-induced cell death
in neonatal rat cardiomyocytes. J. Mol. Cell. Cardiol. 39, 841–844
41. Zhou, P., Hu, J., Wang, X., Wang, J., Zhang, Y., and Wang, C. (2018)
Epidermal growth factor receptor expression affects proliferation and
apoptosis in non-small cell lung cancer cells via the extracellular signal-
regulated kinase/microRNA 200a signaling pathway. Oncol. Lett. 15,
5201–5207
42. Matsui, T., Yamada, N., Kuno, H., and Kanaly, R. A. (2019) Formation of
bulky DNA adducts by non-enzymatic production of 1,2-
naphthoquinone-epoxide from 1,2-naphthoquinone under physiological
conditions. Chem. Res. Toxicol. 32, 1760–1771
43. Parsa, N. (2012) Environmental factors inducing human cancers. Iran. J.
Public Health 41, 1–9
44. Paulsen, C. E., Truong, T. H., Garcia, F. J., Homann, A., Gupta, V.,
Leonard, S. E., and Carroll, K. S. (2012) Peroxide-dependent sulfenylation12 J. Biol. Chem. (2021) 296 100524of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 8,
57–64
45. Miura, T., Kakehashi, H., Shinkai, Y., Egara, Y., Hirose, R., Cho, A. K., and
Kumagai, Y. (2011) GSH-mediated S-transarylation of a quinone glycer-
aldehyde-3-phosphate dehydrogenase conjugate. Chem. Res. Toxicol. 24,
1836–1844
46. Beei, C., Iwamoto, N., Inaba, T., Shinkai, Y., and Kumagai, Y. (2013)
Activation of EGFR/MEK/ERK/AP-1 signaling mediated by 1,2-
naphthoquinone, an atmospheric electrophile, in human pulmonary
A549 cells. J. Toxicol. Sci. 38, 793–797
47. Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N.,
Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., Fish, P., Harsha, B.,
Hathaway, C., Jupe, S. C., Kok, C. Y., et al. (2019) COSMIC: The cata-
logue of somatic mutations in cancer. Nucleic Acids Res. 47, 941–947
48. Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L.,
DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., Xu,
Q., Greulich, H., Thomas, R. K., Paez, J. G., Peck, T. C., et al. (2006)
Epidermal growth factor receptor activation in glioblastoma through
novel missense mutations in the extracellular domain. PLoS Med. 3,
2264–2273
49. Purba, E., Saita, E.-I., and Maruyama, I. (2017) Activation of the EGF
receptor by ligand binding and oncogenic mutations: The “rotation
model. Cells 6, 1–19
50. Nair, S., Trummell, H. Q., Rajbhandari, R., Thudi, N. K., Nozell, S. E.,
Warram, J. M., Willey, C. D., Yang, E. S., Placzek, W. J., Bonner, J. A., and
Bredel, M. (2020) Novel EGFR ectodomain mutations associated with
ligand-independent activation and cetuximab resistance in head and neck
cancer. PLoS One 15, 1–14
51. Izuishi, K., Kato, K., Ogura, T., Kinoshita, T., and Esumi, H. (2000)
Remarkable tolerance of tumor cells to nutrient deprivation: Possible new
biochemical target for cancer therapy. Cancer Res. 60, 6201–6207
52. Jin, Y., Wu, W., Zhang, W., Zhao, Y., Wu, Y., Ge, G., Ba, Y., Guo, Q.,
Gao, T., Chi, X., Hao, H., Wang, J., and Feng, F. (2016) Involvement of
EGF receptor signaling and NLRP12 inflammasome in fine particulate
matter-induced lung inflammation in mice. Environ. Toxicol. 32, 1121–
1134
53. Sakaguchi, M., Watanabe, M., Kinoshita, R., Kaku, H., Ueki, H., Futami, J.,
Murata, H., Inoue, Y., Li, S. A., Huang, P., Putranto, E. W., Ruma, I. M.
W., Nasu, Y., Kumon, H., and Huh, N. H. (2014) Dramatic increase in
expression of a transgene by insertion of promoters downstream of the
cargo gene. Mol. Biotechnol. 56, 621–630
54. Nakahara, K., Fujikawa, K., Hiraoka, H., Miyazaki, I., Asanuma, M., Ito,
A., Takasugi, N., and Uehara, T. (2019) Attenuation of macrophage
migration inhibitory factor-stimulated signaling via S-nitrosylation. Biol.
Pharm. Bull. 42, 1044–1047
55. Abiko, Y., Sha, L., Shinkai, Y., Unoki, T., Luong, N. C., Tsuchiya, Y.,
Watanabe, Y., Hirose, R., Akaike, T., and Kumagai, Y. (2017) 1,4-
Naphthoquinone activates the HSP90/HSF1 pathway through the S-
arylation of HSP90 in A431 cells: Negative regulation of the redox signal
transduction pathway by persulfides/polysulfides. Free Radic. Biol. Med.
104, 118–128
